Thalidomide
- PDF / 141,390 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 58 Downloads / 148 Views
1
S
Neurotoxicity: 9 case reports From a study of 15 patients with refractory aphthous ulceration, nine patients were identified after they developed neurotoxicity while receiving treatment with thalidomide [outcomes not stated]. Six female and three male patients started receiving thalidomide 50mg or 100mg once daily [routes not stated] at 14–52 years of age. Five patients subsequently required a dosage increase to 100mg or 200mg daily due to poor response after 4 weeks. Routine nerve conduction studies (NCS) were used to monitor neurotoxicity. Reduced NCS amplitudes were observed in the patients after 0.8–20 years of thalidomide (cumulative dose 9–290g). Three patients developed associated paraesthesia, while the remaining six patients were asymptomatic. Three of the asymptomatic patients had significant NCS reduction. The three patients with paraesthesia discontinued thalidomide after 8–12 months (cumulative dose 19–44g). Two of the asymptomatic patients with significant NSC decline also stopped thalidomide. However, one woman elected to continued thalidomide therapy, despite having an 80% decline in NCS. The remaining three patients continued to receive thalidomide. Cheng S, et al. Refractory aphthous ulceration treated with thalidomide: A report of 10 years’ clinical experience. Clinical and Experimental Dermatology 37: 132-135, No. 2, Mar 2012. Available from: URL: http://dx.doi.org/10.1111/ 803069992 j.1365-2230.2011.04169.x - United Kingdom
0114-9954/10/1400-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 5 May 2012 No. 1400
Data Loading...
